Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System

References

• Rizzo A. Targeted therapies in advanced cholangiocarcinoma: a focus on FGFR inhibitors. Medicina (Kaunas). 2021;57(5):458. doi: 10.3390/medicina57050458
   PubMed Web of Science ®Google Scholar
• Silverman IM, Li M, Murugesan K, et al. Validation and characterization of FGFR2 rearrangements in cholangiocarcinoma with comprehensive genomic profiling. J Mol Diagn. 2022;24(4):351–364. doi: 10.1016/j.jmoldx.2021.12.012
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32(9):1111–1126. doi: 10.1016/j.annonc.2021.04.012
   PubMed Web of Science ®Google Scholar
• Storandt MH, Jin Z, Mahipal A. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Expert Rev Anticancer Ther. 2022;22(12):1265–1274. doi: 10.1080/14737140.2022.2150168
   PubMed Web of Science ®Google Scholar
• Patel TH, Marcus L, Horiba MN, et al. FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clin Cancer Res. 2023;29(5):838–842. doi: 10.1158/1078-0432.CCR-22-2036
   PubMed Web of Science ®Google Scholar
• Hoy SM. Pemigatinib: first approval. Drugs. 2020;80(9):923–929. doi: 10.1007/s40265-020-01330-y
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684. doi: 10.1016/S1470-2045(20)30109-1
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Kuboki Y, Furukawa M, et al. FIGHT-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies. Cancer Med. 2023;12(9):10597–10611. doi: 10.1002/cam4.5798
   PubMed Web of Science ®Google Scholar
• Shi GM, Huang XY, Wen TF, et al. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: a phase II study. Cancer Med. 2023;12(4):4137–4146. doi: 10.1002/cam4.5273
   PubMed Web of Science ®Google Scholar
• Gong X, Ji T, Liu X, et al. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies. Pharmacol Res Perspect. 2022;10(1):e00906. doi: 10.1002/prp2.906
   PubMed Web of Science ®Google Scholar
• Alekseev O, Ojuok E, Cousins S. Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma. Int J Retina Vitreous. 2021;7(1):34. doi: 10.1186/s40942-021-00305-9
   PubMedGoogle Scholar
• Puar A, Donegan D, Helft P, et al. Hyperphosphatemic tumoral calcinosis with pemigatinib use. AACE Clin Case Rep. 2022;8(5):217–220. doi: 10.1016/j.aace.2022.07.001
   PubMedGoogle Scholar
• Gile JJ, Ou FS, Mahipal A, et al. FGFR inhibitor toxicity and efficacy in cholangiocarcinoma: multicenter single-institution cohort experience. JCO Precis Oncol. 2021;5(5):1228–1240. doi: 10.1200/PO.21.00064
   Google Scholar
• Kommalapati A, Tella SH, Borad M, et al. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers (Basel). 2021;13(12):2968. doi: 10.3390/cancers13122968
   PubMed Web of Science ®Google Scholar
• Böhm R, von Hehn L, Herdegen T, et al. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753.
   PubMed Web of Science ®Google Scholar
• Gatti M, Antonazzo IC, Diemberger I, et al. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol. 2021;28(9):983–989. doi: 10.1177/2047487320915663
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Label [Internet]. U.S. Food and Drug Administration. U.S. Food and Drug Administration (FDA); 2022 [cited 2023 May 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf.
   Google Scholar
• European Medicines Agency. Product information [Internet]. European Medicines Agency; 2022 [cited 2023 May 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf.
   Google Scholar
• Huang L, Guo T, Zalkikar JN, et al. A review of statistical methods for safety surveillance. Ther Innov Regul Sci. 2014;48(1):98–108. doi: 10.1177/2168479013514236
   PubMed Web of Science ®Google Scholar
• Lu Z, Suzuki A, Wang D. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions. BMC Med Res Methodol. 2023;23(1):71. doi: 10.1186/s12874-023-01885-w
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhou P, He N, et al. Drug-induced torsades de pointes: disproportionality analysis of the United States food and drug administration adverse event reporting system. Front Cardiovasc Med. 2022;9:966331. doi: 10.3389/fcvm.2022.966331
   PubMed Web of Science ®Google Scholar
• Shu Y, He X, Liu Y, et al. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. 2022;14:789–802. doi: 10.2147/CLEP.S365513
   PubMed Web of Science ®Google Scholar